Market research
NKTX Nkarta Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 194M
- P/E ratio
- Not available
- Analyst target
- 10.8333
- Dividend yield
- Not available
- Beta
- 0.94
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US65487U1088
- Market cap
- 194M
- P/E ratio
- Not available
- Analyst target
- 10.8333
- Dividend yield
- Not available
- Beta
- 0.94
About
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NKTX discussion.
5 years, 4 months ago
Nkarta, Inc is currently in a long term downtrend where the price is trading 25.5% below its 200 day moving average.
From a valuation standpoint, the stock is 74562.7% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1000000.0.
Based on the above factors, Nkarta, Inc gets an overall score of 0/5.